VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 41

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

272

HTML

2449

Figures (1-3)

216

Tables (1-1)

219

Sum=3156

Nov 7, 2005 (publication date) through Dec 18, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Nov 7, 2005; 11(41): 6429-6432
Published online Nov 7, 2005. doi: 10.3748/wjg.v11.i41.6429

Full Size Figure Download Figure

Figure 3 Comparison of HBsAg (A) and HBV-DNA (B) concentrations between transfection groups.

Citation: Yi J, Gong WD, Wang L, Ling R, Chen JH, Yun J. VP22 fusion protein-based dominant negative mutant can inhibit hepatitis B virus replication. World J Gastroenterol 2005; 11(41): 6429-6432
URL: https://www.wjgnet.com/1007-9327/full/v11/i41/6429.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i41.6429